Ultimovacs ASA (Norway) Market Value
| ULTI Stock | NOK 1.98 0.05 2.46% |
| Symbol | Ultimovacs |
Ultimovacs ASA 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Ultimovacs ASA's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Ultimovacs ASA.
| 10/31/2024 |
| 11/30/2024 |
If you would invest 0.00 in Ultimovacs ASA on October 31, 2024 and sell it all today you would earn a total of 0.00 from holding Ultimovacs ASA or generate 0.0% return on investment in Ultimovacs ASA over 30 days. Ultimovacs ASA is related to or competes with Bergenbio ASA, and PCI Biotech. Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for various cancers More
Ultimovacs ASA Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Ultimovacs ASA's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Ultimovacs ASA upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 50.89 | |||
| Value At Risk | (6.49) | |||
| Potential Upside | 6.55 |
Ultimovacs ASA Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Ultimovacs ASA's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Ultimovacs ASA's standard deviation. In reality, there are many statistical measures that can use Ultimovacs ASA historical prices to predict the future Ultimovacs ASA's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (1.40) | |||
| Treynor Ratio | 0.3731 |
Ultimovacs ASA Backtested Returns
Ultimovacs ASA owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0514, which indicates the firm had a -0.0514% return per unit of risk over the last 3 months. Ultimovacs ASA exposes twenty-four different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Ultimovacs ASA's Risk Adjusted Performance of (0.02), coefficient of variation of (2,287), and Variance of 43.73 to confirm the risk estimate we provide. The entity has a beta of -0.8, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Ultimovacs ASA are expected to decrease at a much lower rate. During the bear market, Ultimovacs ASA is likely to outperform the market. At this point, Ultimovacs ASA has a negative expected return of -0.34%. Please make sure to validate Ultimovacs ASA's kurtosis, daily balance of power, and the relationship between the skewness and accumulation distribution , to decide if Ultimovacs ASA performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.45 |
Average predictability
Ultimovacs ASA has average predictability. Overlapping area represents the amount of predictability between Ultimovacs ASA time series from 31st of October 2024 to 15th of November 2024 and 15th of November 2024 to 30th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Ultimovacs ASA price movement. The serial correlation of 0.45 indicates that just about 45.0% of current Ultimovacs ASA price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.45 | |
| Spearman Rank Test | 0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 0.02 |
Ultimovacs ASA lagged returns against current returns
Autocorrelation, which is Ultimovacs ASA stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Ultimovacs ASA's stock expected returns. We can calculate the autocorrelation of Ultimovacs ASA returns to help us make a trade decision. For example, suppose you find that Ultimovacs ASA has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Ultimovacs ASA regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Ultimovacs ASA stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Ultimovacs ASA stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Ultimovacs ASA stock over time.
Current vs Lagged Prices |
| Timeline |
Ultimovacs ASA Lagged Returns
When evaluating Ultimovacs ASA's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Ultimovacs ASA stock have on its future price. Ultimovacs ASA autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Ultimovacs ASA autocorrelation shows the relationship between Ultimovacs ASA stock current value and its past values and can show if there is a momentum factor associated with investing in Ultimovacs ASA.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Ultimovacs Stock
Ultimovacs ASA financial ratios help investors to determine whether Ultimovacs Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ultimovacs with respect to the benefits of owning Ultimovacs ASA security.